報價延遲最少15分鐘:2026/07/22 03:00 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.235 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.83/-0.81
|
|
企業價值
9.73M
|
| 資產負債 |
|
每股賬面淨值
0.87
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.27M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mentalfatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders. |
